Articles tagged with Multiple Sclerosis
A recent study by I.R.C.C.S. Neuromed found that obese patients with multiple sclerosis have a greater risk of presenting higher EDSS scores and experiencing increased central inflammation. The research suggests that excessive body weight and altered lipid profiles may be associated with worsened clinical expression of the disease.
In a mouse model of atypical EAE, researchers found that dysregulated neutrophils cause damage and exhibit hyper-activated phenotypes, producing excessive reactive oxygen species. Neutralizing treatments reduced disease severity, highlighting the detrimental role of neutrophils in autoimmune neuroinflammation.
The International Pediatric MS Study Group has released updated standards for clinical trials involving children and teens with multiple sclerosis. The new recommendations prioritize pharmacokinetic/pharmacodynamic studies, phase 3 trials in adults considering teenagers, and open-label extension studies to ensure high-quality evidence ...
Researchers found simvastatin helped delay disability worsening and slow brain atrophy in people with secondary progressive MS. The study suggests statins may have independent effects on the disease, beyond cholesterol lowering.
Researchers discovered that fibrinogen, a blood-clotting protein, plays a role in multiple sclerosis relapses. In a mouse model, injecting EVs containing fibrinogen activated CD8+ immune cells, leading to relapsing-remitting disease.
A large-scale assessment of over 20,000 patients found that reading office visit notes offers considerable benefits, particularly for those from underserved populations. Patients reported increased control and understanding of their care, as well as improved adherence to treatment plans and medications.
The study found that out-of-pocket costs for MS drugs increased 20 times between 2004 and 2016, with people in high-deductible plans paying twice as much. The annual cost of treating neurologic disorders in the US is over $500 billion.
A Tel Aviv University study reveals that gene deletion in neurons is responsible for hypersocial behavior in Williams syndrome, caused by myelin sheath deficits. The research also identifies potential treatments using FDA-approved MS drugs.
A scientific breakthrough provides new hope for people with multiple sclerosis, as researchers have developed a compound that stimulates repair of the protective sheath that covers nerve cells in the brain and spinal cord. The study, published in JCI Insight, shows promising results in repairing damaged myelin without severe side effects.
A study by UMass Amherst researchers explores the effects of tai chi and mindfulness meditation on people with multiple sclerosis (MS), comparing their impact on physical balance and psychosocial well-being. The pilot study aims to validate community-based classes and lead to a larger scale study.
A longitudinal study found a correlation between ceramide levels, body mass index, and disease progression in MS patients. Individuals with higher ceramide levels experienced greater loss of motor skills and more brain injury over two years.
A study using 7-Tesla MRI detected cortical lesions in 80% of MS patients, which were strongly correlated with neurological disability and disease progression. Cortical lesions accumulated in grooves on the brain's surface called sulci, suggesting a new approach to evaluating MS progression.
A recent study found that nearly 18% of multiple sclerosis patients were misdiagnosed before receiving treatment at two major Los Angeles medical centers. The study revealed that many patients spent an average of four years being treated for MS before receiving a correct diagnosis.
A Phase 1b clinical trial successfully induces immune tolerance to autoimmune targets in patients with multiple sclerosis and neuromyelitis optica. The treatment involves introducing peptide-loaded tolerogenic dendritic cells, which stimulate the production of IL-10 and promote immune tolerance.
A new study published in Neurology found no link between dietary intake of minerals like zinc, iron, and other minerals with the development of multiple sclerosis. The study involved over 80,000 female nurses and found no association between mineral intake and MS risk.
Researchers optimized a 20-nucleotide DNA aptamer to improve its binding properties to myelin, a promising lead molecule for multiple sclerosis therapy. The study provides the first evidence of cross-reactivity with human brain cells.
Researchers found that brain stem cells from primary progressive MS patients act and look older than normal cells, affecting myelin production. Blocking a specific protein may improve oligodendrocyte growth and offer new treatment options.
A new study attributes the link between earlier puberty and multiple sclerosis (MS) to body mass index (BMI), finding that increased BMI is also linked to a greater risk of MS. Researchers analyzed genetic data from over 329,000 women and found that people with an earlier age of puberty were more likely to develop MS.
A UBC study found that beta interferon treatment for multiple sclerosis patients is associated with a 32% lower mortality risk compared to those who did not take the drug. The study followed nearly 6,000 people with MS in Canada and France over two decades.
Virginia Tech professor Webster Santos has received a grant to discover drugs that inhibit a small molecule transporter, which modulates the immune system and could treat multiple sclerosis. The collaboration aims to develop SPNS2 inhibitors for treating MS and metastatic cancers.
A new study found that non-contrast MRI is just as effective as contrast-enhanced MRI for monitoring disease progression in MS patients. The study used image subtraction techniques to detect newly occurring lesions with high sensitivity.
Researchers examine experiences of families with pediatric onset MS, finding complex diagnostic odyssey and high emotional toll. Disease-modifying treatments improve outcomes, but long-term emotional support needed for patients' families.
A new study found that the risk of relapse in multiple sclerosis (MS) is lower during and after pregnancy than previously thought. Women with MS can have children without an increased risk of relapses, according to a preliminary study published by the American Academy of Neurology.
A study of 135 people with multiple sclerosis found that drinking around 290 calories per day of soda or other sugar-sweetened beverages linked to more severe symptoms and a higher level of disability. Those who seldom consumed these beverages had less severe symptoms, highlighting the potential negative impact on MS progression.
Researchers found that high flavonoid cocoa powder improved fatigue in people with multiple sclerosis by reducing mental and physical fatigue. Participants who drank the high flavonoid version showed a moderate effect on fatigability and improvements in pain symptoms, while those drinking low flavonoid cocoa saw no significant benefits.
Researchers at the Advanced Science Research Center have identified a mechanism by which metabolites inhibit epigenetic changes in brain-homing immune cells, which play a key role in multiple sclerosis. The discovery could lead to more specific and effective MS therapies.
Researchers will examine how individuals with MS process outcomes of their actions during cooperative interactions, aiming to maximize their competence in social interactions. The study will focus on the impact of delayed reciprocation vs immediate reciprocation on outcome processing in individuals with MS.
A new study from the University of British Columbia found that neighbourhood income and education level are associated with an increased risk of disability progression in patients with multiple sclerosis. The research suggests that modifiable lifestyle factors, such as diet and exercise, could be involved in this relationship.
Dr. Ekaterina Dobryakova, a researcher at Kessler Foundation, has been honored with the International Neuropsychological Society's Early Career Award for her work on traumatic brain injury and multiple sclerosis. Her research focuses on noninvasive interventions to address cognitive deficits caused by these conditions.
Researchers have developed a new compound that shows promise in treating multiple sclerosis by reducing inflammation and promoting neuroprotection and remyelination. The compound, based on chloroindazole, has been found to be effective in improving primary symptoms in a mouse model of the disease.
Researchers created a high-resolution map of the brain's immune system, showing that all microglia have the same core signature but adapt differently depending on their function. This discovery is significant for understanding brain diseases like multiple sclerosis and Alzheimer's.
A new study found that multiple sclerosis patients with food allergies experienced a higher rate of disease activity and increased likelihood of new lesions compared to those without food allergies. The association highlights the potential role of the gut in MS immune dysregulation.
A team of scientists discovered that Blimp1 prevents the loss of identity in regulatory T cells, a type of immune cell that controls inflammation. This finding has implications for therapies against inflammatory autoimmune diseases such as multiple sclerosis and arthritis.
A recent study published in Nature Communications identifies Satb1 as a protein regulator that induces the pathogenic properties of Th17 cells, leading to multiple sclerosis and other inflammatory autoimmune disorders. By targeting Satb1 gene expression in Th17 cells, novel treatments may be developed to alleviate or eliminate disease ...
Researchers at University of Freiburg discover new immune cells that promote multiple sclerosis development, creating an immune cell atlas for the brain. Chronic activation of these cells may explain why the brain is chronically attacked in MS patients.
Researchers found that Medicare patients with multiple sclerosis spend $6,894 a year out of pocket for treatment. This is attributed to the lack of incentives for companies not to raise prices, leading to restrictive policies and high coinsurance cost-sharing models.
A team of researchers has identified a mechanism that contributes to the degeneration of axons in multiple sclerosis, leading to permanent neurological deficits. They found that minuscule ruptures in the cell membrane allow calcium ions to enter the neuron, disrupting its balance and ultimately killing it.
A study published in Nature found that people with multiple sclerosis have different types of oligodendrocytes than healthy individuals, which may explain why their myelin repair process does not work as well. This discovery could lead to the development of new treatments for progressive MS.
Researchers found that older cells in MS patients can reform myelin, but new oligodendrocyte generation is severely limited. This suggests treating MS aggressively at an early stage is crucial to prevent further damage.
A team from Charité has identified the Chi3l3 protein as a key player in the body's innate ability to repair damaged myelin sheaths in multiple sclerosis. By understanding this molecular signal, researchers aim to develop new drugs that can restore electrical insulation around nerve cells.
A new systematic approach has identified environmental factors that boost neurological inflammation, including an herbicide banned in Europe. Researchers found that linuron and another compound increase activity of a gene associated with inflammation.
Researchers at the University of Chicago Medical Center have found a promising treatment for multiple sclerosis, a disabling immune-mediated disease that damages nerve fibers. Sephin1, a small molecule, may delay harm to nerve cells by protecting oligodendrocytes and reducing inflammation.
International study finds MS treatments can delay secondary progressive stage of the disease by five years or more, improving quality of life. Early treatment is essential to prevent worsening disability and irreversible loss of function.
Gut immune cells, specifically plasma cells producing Immunoglobulin A antibodies, migrate to the central nervous system and produce an anti-inflammatory effect during MS flare-ups. Increasing these cells blocks inflammation entirely in a preclinical model of the disease.
The proposal calls for pharmaceutical companies to collect post-marketing data in all minority groups, classifying responsiveness based on ethnicity. Package labelling should include efficacy data from minority populations.
A University at Buffalo team discovered that activation of PRRX1 induces pathological quiescence, rendering adult stem cells incapable of producing myelin-forming oligodendrocytes. This finding presents a novel approach to developing treatments for multiple sclerosis and other inflammatory diseases by blocking pathological quiescence.
Research published in the Journal of Neurology & Psychiatry found that food allergies are associated with a higher rate of cumulative disease bouts and active disease in multiple sclerosis patients. The study analyzed data from 1349 adults and found that food allergy was linked to a 27% higher rate of disease flare-ups.
Researchers at Karolinska Institutet discovered that oligodendrocytes, cells responsible for myelin production, may play a significant role in MS development. This finding could lead to new therapies targeting areas beyond the immune system.
Researchers found that the thymus, a small organ near the heart, maintains its output of T cells during pregnancy, which is essential for protecting against infection while tolerating the fetus. The study's findings may have implications for understanding autoimmune diseases like multiple sclerosis.
A recent study published in Nature Immunology found that B cell accumulation triggers nervous system damage in MS patients. The presence of myeloid-derived suppressor cells (MDSCs) regulates the number of B cells, and their absence leads to inflammation and tissue damage.
Researchers are conducting a randomized controlled trial to investigate the effects of treadmill walking exercise training on learning and memory performance, hippocampal volume, and resting-state functional connectivity in people with Multiple Sclerosis (MS). The study aims to determine if aerobic exercise can improve cognitive defici...
A new study finds that pelvic floor muscle exercises can significantly improve overactive bladder symptoms in patients with neurogenic and non-neurogenic conditions. The study suggests that PFM training activates the frontal cortex of the brain, leading to improved conscious control of bladder function.
A Yale-led team has identified four new genetic variants that directly damage gene sequences, accounting for an additional 5% of MS disease risk. The findings contradict previous theories on the role of common genetic variants in MS, providing promising new avenues for research and study.
A new conceptual framework proposes examining exercise effects on brain connectivity, structure, and molecular mechanisms in multiple sclerosis. This systematic approach may lead to new strategies for rehabilitative care and treatment.
Researchers found structural changes in myelin sheaths triggered by environmental factors can lead to autoimmune attacks that cause MS. The study suggests even minor changes in local conditions may precipitate the disease.
A recent study by the MAGNIMS Study Group provides new insights into the involvement of the hippocampus in multiple sclerosis, a neurodegenerative disease that affects cognition. The research suggests that modifying the hippocampus through aerobic exercise and memory retraining may be effective in improving cognitive outcomes for MS pa...
Researchers discovered that herpesvirus 6 infection before inducing EAE significantly accelerated the disease's progression in marmosets. This finding supports the hypothesis that viral infections can increase susceptibility to autoimmunity by triggering a heightened immune state.
Scientists have developed an antibody that blocks the inflammatory and oxidative activity of fibrin, a blood protein that contributes to neurodegeneration in the brain. The treatment has shown promise in reducing inflammation and neurodegeneration in both mouse models of multiple sclerosis and Alzheimer's disease.
A systematic review and meta-analysis of 17 clinical trials found that medical marijuana reduced subjective patient assessments of spasticity, pain, and bladder dysfunction in patients with multiple sclerosis. However, the therapy may carry a higher risk of adverse events compared to placebo.
New findings suggest that the immune system's response to a protein called GDP-L-fucose synthase, found in both human cells and bacteria, may play a key role in multiple sclerosis. The protein is believed to activate T cells in the intestine, leading to an inflammatory cascade that damages the protective coating around nerve cells.